The peptide supplement market runs on a specific type of scientific-sounding content that is hard to immediately classify as false. The citations are real. The mechanisms are real. The studies exist. What's missing is the part where the specific claim you're being sold is actually supported by those studies — and that gap is usually where the money is.

Here is a practical framework for evaluating any peptide claim before it costs you money, health risk, or both.

Question 1: What species was the evidence generated in?

This is the first filter and the one most frequently omitted from peptide marketing. The claim hierarchy in biomedical research runs: in vitro (cell culture) → animal model → human clinical trial. Most peptide marketing cites studies from the bottom of that hierarchy to make claims appropriate only for the top.

"BPC-157 accelerates tendon healing" is well-supported in rat models. In human tissue? No completed trials. These are different claims, and conflating them is the foundation of most peptide misinformation.

When you see a claim, ask: where was this demonstrated? If the answer is "rats" or "cell culture," the evidence chain has at least one more step before it applies to you.

Question 2: What was the sample size?

Many influential peptide studies were conducted in groups of 8-15 animals. These are acceptable pilot studies for generating hypotheses. They are not definitive evidence of efficacy. Small samples produce noisy results, and noisy results don't replicate consistently even in similar animal studies.

When a claim says a peptide "significantly improved" some outcome, find the n. An n of 10 with a p-value of 0.04 means something different than an n of 200 with a p-value of 0.04. The latter is evidence. The former is a signal that merits investigation.

Question 3: Has it been independently replicated?

Independent replication — different research groups, different labs, different countries, confirming the same finding — is the mechanism through which preliminary results become established science. A single research group publishing consistent positive results from the same compound over many years is not the same as independent replication. Check who funded the studies and whether the findings have been reproduced outside the original group.

Dihexa's "100,000x more potent than BDNF" claim, for example, comes from a single research group's cell culture paper and has not been substantively replicated. That's a fact worth knowing before attributing superhuman nootropic properties to the compound. See what the evidence actually shows for Dihexa.

Question 4: Is there a completed human clinical trial?

The most important question. Animal and in vitro evidence is hypothesis-generating, not hypothesis-confirming. Humans are not large rats. Our metabolism, tissue distribution, pharmacokinetics, and response to foreign peptides differ from rodents in ways that consistently surprise researchers who assumed translation would be straightforward.

You can check ClinicalTrials.gov for registered human trials. The status matters: "completed" with published results is very different from "terminated early" or "recruiting." A recruiting trial means someone is testing it — not that it works.

For most peptides currently being marketed, you will find one of three things: no registered trials, a Phase I trial (safety/pharmacokinetics only, no efficacy data), or a Phase II trial with inconclusive or negative results. Finding a completed Phase III trial with positive results would be notable enough that the compound would likely be FDA-approved and sold as a pharmaceutical, not a research chemical.

Question 5: What is the quality of the source material?

This is a separate question from efficacy but equally important for safety. Most peptides sold for human use in the US are classified as "research chemicals" — legal to purchase but not approved for human consumption. This means no FDA oversight of manufacturing standards, no required quality testing, no enforced labeling accuracy.

Studies have found gray-market peptides with incorrect concentrations, wrong compounds, bacterial contamination, and residual organic solvents from synthesis. The peptide that performed well in a controlled rat study was pharmaceutical-grade material. What you're ordering may not be.

Some compounding pharmacies produce peptides under stricter quality controls, but this adds cost and typically requires a physician's prescription. If you're getting peptides from a website with no sourcing transparency, you're accepting unknown material risk on top of unknown efficacy risk.

Question 6: What are the incentives of the person making the claim?

Most people promoting peptide protocols online have financial relationships with suppliers, earn affiliate commissions, sell courses or stacks, or build audience through aspirational content. None of these incentives are aligned with accurately representing uncertainty.

This doesn't mean everyone selling peptide information is dishonest. It means the information environment rewards confident claims over calibrated ones, and you should weight your sources accordingly. A forum post from someone selling nothing and citing primary literature is worth more than a polished YouTube video from someone with a discount code.

Question 7: What specifically is being claimed?

Peptide marketing is skilled at keeping claims vague enough to be hard to falsify. "Supports recovery" is not a testable claim. "Heals torn ligaments in 2 weeks" is — and when you score that specific claim against the evidence, the BS score is high.

When evaluating a peptide, push for the specific claim: not "BPC-157 is good for healing" but "BPC-157 at X dose administered via Y route reduces recovery time for Z injury type in humans by W percent." That's what you'd need to know to make a decision. Most peptide content will never give you that, because the evidence to support it doesn't exist.

A Practical Workflow

When you encounter a peptide claim:

  1. Identify the specific, falsifiable claim being made
  2. Search PubMed for the compound name + claimed effect
  3. Note: species, sample size, funding source, and whether it was replicated
  4. Check ClinicalTrials.gov for human trial status
  5. Apply a prior: most things that look good in rodents don't replicate at the same magnitude in humans

Or skip steps 1-5 and run the claim through PinPrick's scorer — it applies this framework automatically and returns a calibrated BS score against the published evidence. The goal is the same: replace "sounds promising" with "here's what we actually know."

The Baseline Expectation

The reasonable prior for any peptide claim is skepticism proportional to the gap between what's being claimed and what the evidence supports. Most peptides being actively marketed have real mechanisms and interesting preclinical data. Almost none of them have completed human efficacy trials for the specific use case being marketed. That gap — between interesting preclinical signal and proven human efficacy — is where most of the money in the peptide industry lives.

Understanding that gap doesn't mean peptides are useless. It means the honest framing is "early-stage compound with promising preclinical data and unknown human efficacy," not "clinically proven protocol." The first is interesting. The second is a marketing claim. Only one of them is honest.